Investor Claims Against Cancer Drug Maker Survive Dismissal Bid

Mealey's (August 6, 2021, 1:53 PM EDT) -- SAN DIEGO — A federal judge in California on Aug. 4 declined to grant a motion to dismiss filed by a pharmaceutical company and certain of its senior executives on claims that they misrepresented adverse clinical trial results for the company’s metastatic breast cancer (MBC) treatment candidate in violation of federal securities laws, ruling that the lead plaintiff in the action sufficiently pleaded falsity and scienter in bringing his claims....